A first U.S. patient treated with Imviva’s allogeneic anti‑CD7 CAR‑T, CTD402, in the TENACITY‑01 study achieved a complete remission with incomplete hematologic recovery (CRi) after manageable adverse events and early discharge, enabling consolidation with transplant. The company also cites earlier exploratory experience showing a 64.1% complete remission rate with 91.7% MRD negativity in relapsed/refractory T‑ALL/LBL, providing directional context ahead of formal readouts.
The core development is the initiation of U.S. dosing in TENACITY‑01 (NCT07070219), a global, single‑arm, open‑label Phase 1b/2 program in adolescents and adults with relapsed/refractory T‑ALL/LBL. Phase 1b will enroll roughly 36 patients split between dose exploration and the recommended Phase 2 dose, followed by a 36‑patient Phase 2. All participants receive fludarabine/cyclophosphamide lymphodepletion and a flat 400×10^6‑cell dose. Interim Phase 1b data are guided for mid‑2026, with overall study completion targeted for late 2028. CTD402 incorporates TCR and HLA class II knockouts and proprietary inhibitory ligands aimed at reducing graft rejection, and is positioned as a ready‑at‑point‑of‑care product. The asset holds RMAT and Rare Pediatric Disease designations. Separately, Bioheng Therapeutics has rebranded to Imviva Biotech as the company expands globally.
Strategically, this is an execution play to validate an off‑the‑shelf CD7‑directed CAR‑T in a setting where autologous products are slowed by manufacturing timelines and, in T‑cell malignancies, by the risk of malignant contamination. A standardized dose and conventional lymphodepletion simplify site operations and align with routine cell therapy workflows, but also put pressure on the product’s persistence and resistance to host rejection—historically challenged domains for allogeneic platforms. The single‑arm design signals reliance on historical controls, while RMAT status provides a path for frequent regulatory engagement if early efficacy and safety signals cohere.
For sites, an allogeneic option removes apheresis scheduling and shortens vein‑to‑treatment intervals, which could reduce the need for aggressive bridging in fast‑moving disease. It also concentrates operational risk in infection prophylaxis, monitoring of T‑cell aplasia, and coordination with transplant teams when remission is achieved. Sponsors and CROs will be managing the usual cellular kinetics sampling, plus donor‑ and lot‑level traceability to satisfy comparability expectations as manufacturing scales. Regulators will focus on incidence and severity of CRS and ICANS, any graft‑versus‑host disease, on‑target immunosuppression, and the durability of MRD‑negative responses pre‑ and post‑transplant. Payers and HTA bodies will look for clear benchmarks against historical salvage outcomes and clarity on where the therapy sits relative to transplant—bridge, alternative, or both.
Near term, the key watch items are reproducibility of early remissions across the first 10–20 patients, the rate and grading of immune‑mediated toxicities and opportunistic infections, and persistence of CTD402 in the face of standard lymphodepletion. The study’s flat dosing will help test inventory efficiency but raises the usual allogeneic questions around dose intensity versus rejection risk. If the Phase 1b signal supports a rapid transition to Phase 2, Imviva will also need to demonstrate lot‑to‑lot consistency and adequate global manufacturing capacity to keep timelines intact. The rebrand underscores an intent to compete beyond China‑originated data, but the bar will be the ability to generate U.S. and multi‑region evidence with robust MRD‑negative CR and 6–12‑month durability. As multiple CD7‑directed programs advance, differentiation will hinge on operational speed, safety profile, and how convincingly sponsors can position allogeneic CAR‑T within transplant‑centered care pathways.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
